- A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
- Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms
- Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)
- Experimental Vaccine for Prevention of Ebola Virus Infection
- Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
- Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
- Phase 1 Trial of Ebola Vaccine in Mali
- Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
- Treatment of Hemorrhagic Fever With Ribavirin
Clinical Trials
- A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease
- A Study of Mycophenolate Mofetil Combined With Glucocorticoid Therapy in Relapse Vogt-Koyanagi-Harada Disease
- Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease
- A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)
- A Study of mRNA-3745 in Participants With Glycogen Storage Disease Type 1a (GSD1a)
- Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I
- Biomarker for Glycogen Storage Diseases (BioGlycogen)
- Clinical Evaluation of a Non-Invasive Hypoglycemia Detector in a Glycogen Storage Disease Population
- Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial
- Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia
- Glycosade v UCCS in the Dietary Management of Hepatic GSD
- Long-Term Follow-up to Evaluate the Safety and Efficacy of Adeno Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6-Phosphatase (G6Pase) in Adults With Glycogen Storage Disease Type Ia (GSDIa)
- Overnight Feeding Study in Glycogen Storage Disease Type 1
- Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin
- Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa
- Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)
- Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency
- Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease
- The Use of Uncooked Sweet Polvilho to Treat Hepatic Glycogen Storage Diseases
- 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
- 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
- A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma
- A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
- Assessment of Residual VHL Function in Tumors – Can it Predict the Patients’ Individual Course of Disease?
- Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
- Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
- Drivers of Hypoxia-induced Angiogenesis in Tumor Development
- Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
- Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
- Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
- EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
- Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome
- Metabolic Mapping to Measure Retinal Metabolism
- MyVHL: Patient Natural History Study
- National Eye Institute Biorepository for Retinal Diseases
- Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
- Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- Pazopanib in Von Hippel-Lindau (VHL) Syndrome
- Phase II Study of Vandetanib in Individuals With Kidney Cancer
- Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease
- Propranolol and Von Hippel-Lindau Disease
- PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
- Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
- Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma
- Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients
- Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease
- Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease
- Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome
- TKI 258 in Von Hippel-Lindau Syndrome (VHL)
- Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
- Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
- Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
- Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
- Von Hippel-Lindau Disease Genetic Epidemiology Study
- A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
- A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer
- A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters for the Treatment of Vulva Cancer
- A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
- A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
- A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
- A Survivorship Care Plan for Gynaecological Cancer Patients
- Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers
- Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
- Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
- Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
- Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
- Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
- CaptHPV : Validation of the Method “CaptHPV” for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas
- ChemoFx® PRO – A Post-Market Data Collection Study
- Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.
- Chemoradiation-Induced Nausea and Emesis: Quality of Life
- Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva
- Cisplatin+Pembrolizumab+RT in Vulvar Cancer
- Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer
- Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients.
- Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer
- Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
- E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
- E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
- Early Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study
- Education, Immigration and HPV Vaccination: an Informational Randomized Trial
- Effectiveness of an Individualized Symptom Education Program (ISEP)
- Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
- Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer
- Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
- Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
- Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
- Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
- Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva
- Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer
- Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
- Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy
- Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- Gynaecology Exercise and Mindfulness Study
- HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
- Image-Guided Gynecologic Brachytherapy
- Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
- Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
- Indocyanine Green Fluorescence Imaging, Sentinel Lymph Node Mapping in Patients With Vulvar Cancer
- Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention
- Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
- Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
- Longitudinal Evaluation of Women Undergoing Pelvic Exenteration for Treatment of Gynecologic Malignancy
- Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva
- Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer
- MR-HIFU for Recurrent Gynaecological Cancer
- Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study
- Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
- OCT-AF Imaging of Pre-cancers of Vulva and Cervix
- Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
- Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life
- Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva
- Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
- Pelvic Floor Disorders in Survivors of Gynecologic Malignancies
- Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies
- Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
- Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients
- Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer
- Quality of Life, Unmet Needs and Satisfaction With Care After Vulvar Cancer
- Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes
- Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva
- Retrospective Study of Brachytherapy
- Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.
- Self-Advocacy Serious Game in Advanced Cancer
- Sentinel Node Extended in Squamous Cell Vulvar Cancer
- Serial MRI Scans During Radiation Therapy
- STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision
- Study to Evaluate the Role of PlasmaJet in Patients Undergoing Groin Node Dissection for Vulval Cancer
- Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer
- The Impact of the “WOMAN-PRO II Program” on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence
- The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study
- Topical Imiquimod in Treating Patients With Recurrent Paget’s Disease of the Vulva
- Ultrasound Morphometric and Cyto/Histological Combined Pre-operative Assessment of Inguinal Lymph Node Status in Women With Invasive Vulvar Carcinoma
- Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
- Validation of a Nutrition Screening Tool
- Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
- “Vestibulitis Educational Seminar Trial” Study
- 5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis
- A Search for Helicobacter Pylori in Localized Vulvodynia
- Acupuncture for the Treatment of Vulvodynia
- Acupuncture for Vulvodynia: A Pre-pilot Study
- Botox on Vulvar Vestibulitis
- Cold Laser: A Modality to Promote Vulvar Healing and Pain Relief
- Dysbiosis in Localized Provoked Vulvodynia (LPV)
- Effect of Acupuncture on Patient Vulvodynia Outcomes
- Effect of Two Acupuncture Protocols on Vulvodynia
- Effectiveness of Cognitive Behavioural Therapy and Physical Therapy for Provoked Vestibulodynia
- Effects of Flourish HEC on Localized Provoked Vulvodynia
- Pregabalin for the Treatment of Vulvodynia
- Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin’s Lymphoma After Autologous Stem Cell Transplantation
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin’s Lymphoma or T-cell Lymphoma
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
- A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies
- A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies
- A Phase 1 Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
- A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
- A Phase II Study of Carfilzomib in Relapsed Waldenström’s Macroglobulinemia (WM) IST-CAR-531
- A Phase II Study of Doxycycline in Relapsed NHL
- A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia
- A Phase II Trial of Ofatumumab in Subjects With Waldenstrom’s Macroglobulinemia
- A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
- A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
- A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström’s Macroglobulinemia (WM)
- A Study for Patients That Have Been Previously Been Treated in Waldenstrom’s Macroglobulinemia or Multiple Myeloma
- A Study of ARQ 531 in Patients With Selected Hematologic Malignancies
- A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
- A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
- A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom’s Macroglobulinemia (WM)
- A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom’s Macroglobulinemia (WM)
- A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
- A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom’s Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom’s Macroglobulinemia
- A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
- ACALA-R In Anti-MAG Neuropathy Mediated Neuropathy
- Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
- ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
- Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
- Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
- Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
- Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
- Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Allo HSCT Using RIC for Hematological Diseases
- Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
- An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenström Macroglobulinemia
- Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom’s Macroglobulinemia
- Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom’s Macroglobulinemia
- APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
- B-Cell Hematologic Malignancy Vaccination Registry
- Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
- Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
- Bendamustine, Rituximab and Acalabrutinib in Waldenstrom’s Macroglobulinemia
- Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
- BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
- Bortezomib (Velcade) in Waldenstrom’s Macroglobulinemia
- Bortezomib and Filgrastim in Promoting Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Stem Cell Transplant
- Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
- Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia
- Bortezomib and Rituximab for Patients With Waldenstrom’s Macroglobulinemia
- Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
- Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom’s Macroglobulinemia
- Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia
- Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
- BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)
- Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
- Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
- Carfilzomib, Rituximab and Dexamethasone in Waldenstrom’s Macroglobulinemia
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
- CC-5013 (Lenalidomide) and Rituximab in Waldenstrom’s Macroglobulinemia
- CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia
- Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia
- Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
- CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
- Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
- Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
- Combination Bortezomib and Rituximab in Patients With Waldenstrom’s Macroglobulinemia
- Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
- Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia
- Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
- Copanlisib and Nivolumab in Treating Participants With Richter’s Transformation or Transformed Indolent Non-Hodgkin’s Lymphoma
- Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom’s Macroglobulinemia
- Covid-19 Vaccine Responsiveness in MM and Waldenstrom
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
- Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm’s Macroglobulinemia
- Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
- Dasatinib In Waldenström Macroglobulinemia
- Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
- Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
- Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
- Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
- DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom’s Macroglobulinemia Patients
- Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom’s Macroglobulinemia
- Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
- Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
- Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia
- Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenström’s Macroglobulinemia
- Efficacy of First Line B-RI for Treatment Naive Waldenström’s Macroglobulinemia
- Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström’s Macroglobulinemia
- Efficacy of Venetoclax in Combination With Rituximab in Waldenström’s Macroglobulinemia
- Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
- ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
- Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia
- Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
- Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
- Everolimus (RAD001) in Primary Therapy of Waldenstrom’s Macroglobulinemia
- Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
- Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom’s Macroglobulinemia
- Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
- Expression of Ku70/XRCC6 in Waldenström’s Macroglobulinemia
- Extension Study of IMO-8400 in Patients With Waldenström’s Macroglobulinemia Who Completed Study 8400-401
- Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia’s
- FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
- Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
- First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.
- Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
- Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
- Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
- Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
- Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
- Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
- Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
- Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
- Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
- Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
- Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
- Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
- Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
- HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
- Ibrutinib (PCI-32765) in Waldenstrom’s Macroglobulinemia
- Ibrutinib + Venetoclax in Untreated WM
- Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia
- Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
- Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
- Ibrutinib With Rituximab in Adults With Waldenström’s Macroglobulinemia
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
- Imexon for Relapsed Follicular and Aggressive Lymphomas
- Immune Responses to COVID-19 Vaccination in Lymphoma Patients
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
- Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease
- Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström’s Macroglobulinaemia
- Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma
- Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
- Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer
- Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
- LBH589 in Relapsed or Relapsed and Refractory Waldenstrom’s Macroglobulinemia
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
- Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
- Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
- Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
- Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
- Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
- Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- Loncastuximab Tesirine in WM
- Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
- Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
- Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
- Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood
- MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
- Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin’s Lymphoma
- Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
- MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
- MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
- Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators’ Expression in Allogeneic SCT Using FluBuATG
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
- Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
- NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
- Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström’s Macroglobulinemia and in IgM-MGUS
- Nonmyeloablative Allogeneic Transplant
- Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom’s Macroglobulinemia
- Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
- Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
- Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
- Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
- Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
- Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
- Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
- Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
- Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
- Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
- Perifosine in Patients With Relapsed/Refractory Waldenstrom’s Macroglobulinemia
- Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
- Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
- Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom’s Macroglobulinemia
- Phase II Study of Campath-1H Antibody to Treat Waldenstrom’s Macroglobulinemia
- Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
- Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
- Pomalidomide, Dexamethasone and Rituximab in Waldenstrom’s Macroglobulinemia
- Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia
- PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
- PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
- PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
- Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
- R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom’s Macroglobulinemia
- Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
- Randomised Trial in Waldenstrom’s Macroglobulinaemia
- Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
- Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
- Rifaximin in Patients With Monoclonal Gammopathy
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin’s Lymphoma
- Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
- Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström’s Macroglobulinaemia
- Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
- Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin’s Lymphoma
- Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
- RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
- S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
- Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
- Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
- Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
- Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
- SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin’s or Non-Hodgkin’s Lymphoma
- Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
- Serologic Response to a New Recombinant, Adjuvanted Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia Treated With First-Line BTK Inhibitors
- Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
- Sildenafil Citrate in Waldenstrom’s Macroglobulinemia
- Simvastatin in Waldenstrom’s Macroglobulinemia
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
- Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
- Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function
- Spanish Registry of Patients With IgM Monoclonal Gammopathies
- Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
- Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
- Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
- Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
- Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
- Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
- Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström’s Macroglobulinemia (WM)
- Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)
- Study of Epratuzumab (hLL2) in Patients With Waldenstrom’s Macroglobulinemia
- Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
- Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom’s Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
- Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
- Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Study of MLN8237 in Participants With Advanced Hematological Malignancies
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
- Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
- Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
- Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia
- Study of SGR-1505 in Mature B-Cell Neoplasms
- Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
- Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
- Study of VTD in Waldenstrom’s Macroglobulinemia
- Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
- Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin’s Lymphoma
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
- T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
- Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
- Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
- Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
- Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
- Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom’s Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Thalidomide and Rituximab in Waldenstrom’s Macroglobulinemia
- Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
- The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
- The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
- The Master Registry of Oncology Outcomes Associated With Testing and Treatment
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
- Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Treatment of Chinese Patients With B-Cell Malignancies With BGB-16673, a Burton Tyrosine Kinase-Targeted Protein-Degrader
- Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
- Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
- Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
- Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom’s Macroglobulinemia
- Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
- UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
- Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
- Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma
- Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
- Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
- Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
- Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
- Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
- Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
- Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
- Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
- Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
- Zanubrutinib in Patients With Waldenström’s Macroglobulinemia (ARIADNE)
- Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom’s Macroglobulinemia
- A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis
- Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s)
- Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis
- Alemtuzumab for ANCA Associated Refractory Vasculitis
- American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
- An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis
- An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
- Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis
- Anti-Cytokine Therapy for Vasculitis
- Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography
- Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
- BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
- Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
- Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis
- Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis
- Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
- Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA
- Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes
- Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
- Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
- Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
- Daclizumab to Treat Wegener’s Granulomatosis
- Diagnostic Effectiveness of Virtual Bronchoscopy
- Educational Needs of Patients With Systemic Vasculitis
- Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Efficacy Study of Two Treatments in the Remission of Vasculitis
- Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.
- Etanercept for Wegener’s Granulomatosis
- Etanercept to Treat Wegener’s Granulomatosis
- Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
- Hydroxychloroquine in ANCA Vasculitis Evaluation
- Impact of Vasculitis on Employment and Income
- Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
- Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”)
- Journey of Patients With Vasculitis From First Symptom to Diagnosis
- Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis
- Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
- Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
- Low-dose Glucocorticoid Vasculitis Induction Study
- Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.
- Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA)
- Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions
- Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study
- Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis)
- Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
- One-Time DNA Study for Vasculitis
- Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis
- Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis
- Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
- Plasma Exchange for Renal Vasculitis
- PR3-AAV Resilient Remission or PRRR
- PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis
- Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
- PRO Development for ANCA Associated Vasculitis
- Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
- RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
- Reproductive Health in Men and Women With Vasculitis
- Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS
- Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
- Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis
- Rituximab Vasculitis Maintenance Study
- Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
- Steroids and Methotrexate to Treat Systemic Vasculitis
- Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
- Study of One Protein Implicated in Wegener Disease
- Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
- Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
- TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
- The ANCA Vasculitis Questionnaire (AAV-PRO©)
- The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach
- The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach
- Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
- Treatment of Wegener’s Granulomatosis With Cyclophosphamide
- Vasculitis Illness Perception (VIP) Study
- Vasculitis Pregnancy Registry
- VCRC Patient Contact Registry Patient-Reported Data Validation Study
- VCRC Tissue Repository
- Yellow Fever Vaccine in Patients With Rheumatic Diseases